1. The overview of “Teva Pharmaceuticals”
2. The detailed data of “Teva Pharmaceuticals”
3. The map of “Teva Pharmaceuticals”
4. The stock weekly chart of “Teva Pharmaceuticals”
5. The stock weekly trading radar of “Teva Pharmaceuticals”
6. The annual filings of “Teva Pharmaceuticals”
7. The stock price of “Teva Pharmaceuticals”
* Last update: July 20, 2021
The overview of “Teva Pharmaceuticals”
“Teva Pharmaceutical Industries Ltd.“, founded in 1901, is a global pharmaceutical company with headquarters in Petah Tikva, Israel. It was given the current name on May 1, 1935. The company’s facilities are located in Israel, North America, South America, Europe, and Australia, and it specializes in generic drugs, business for pharmaceutical ingredients and proprietary pharmaceuticals. Also, it’s the eighteenth largest pharmaceutical company in the world.
In 2000, “Teva Pharmaceuticals” acquired Canada-based “Novopharm”, German generic “Ratiopharm” for 5 billion USD in August 2010, US-biopharmaceutical company “Cephalon” for 6.8 billion USD in May 2011, and Japanese generic drug company “Taiyo Pharmaceutical Industry” for 40 billion JPY in the same year. The company’s stocks are listed on not only the Tel Aviv Stock Exchange, but also the New York Stock Exchange (NYSE).
The detailed data of “Teva Pharmaceuticals”
●Established date： 1901
●Location： 5 Basel St, Petach Tikva 49131, Israel
●Stock Exchange： NYSE（TEVA）
●Listing date： 2012
●Business details： Development and marketing of drugs（Biotechnlogy）
The map of “Teva Pharmaceuticals”
The stock weekly chart of “Teva Pharmaceuticals”
The stock weekly trading radar of “Teva Pharmaceuticals”
The annual filings of “Teva Pharmaceuticals”
* U.S. dollars in millions
|Cutoff date||December 31, 2020||December 31, 2019|
|Net income attributable||(3,990)||(999)|
|Total current assets||13,005||13,464|
|Total current liabilities||13,164||13,674|
(1.2 or more is the best)
|Common stock and additional paid-in capital||27,500||27,368|
|Retained earning, Accumulated deficit||(10,946)||(6,956)|
|Total stockholders' equity||11,061||15,063|
|Total equity and liabilities||50,640||57,470|
(20% or more is better)
(50% or more is the best)
|Cash flows from operating activities||1,216||748|
|Cash flows from investing activities||863||1,355|
|Cash flows from financing activities||(1,885)||(1,926)|
|Free cash flow||2,079||2,103|
The stock price of “Teva Pharmaceuticals”
Loss from operations expanded and Accumulated deficit increased.
Equity ratio declined, but it's not bad situation because of more than 20%.
As much as possible, it might be better that Current ratio are raised in order to aim Retained earning.
The stock price of "Teva Pharmaceuticals" in 2021 might tend to be stagnant as well as 2020.
|Entity min stock price in monthly chart||N/A||approx 8.6 (Apr)|
|Entity max stock price in monthly chart||N/A||approx 12.6 (Jun)|
|Stock price increase ratio|
(50% or more is the best)